Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354190 | 0.95 | CA1 (0.49) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL354116 | 0.87 | MTNR1A (0.48) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL354268 | 0.86 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL10253259 | 0.86 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL355453 | 0.85 | HDAC8 (0.60) | HDAC8HDAC6 | |
| SCHEMBL354112 | 0.85 | HDAC8 (0.60) | HDAC8HDAC6 | |
| SCHEMBL469781 | 0.83 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL15985126 | 0.82 | MTNR1A (0.40) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL464149 | 0.82 | MTNR1A (0.50) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL17478386 | 0.81 | CA1 (0.48) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MTNR1A 1476/4885MTNR1B 944/4885CA1 506/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | MTNR1A 1616/4885MTNR1B 1109/4885CA1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.